A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.

• DOI: 10.1200/jco.2024.42.16_suppl.e18013
• Publication Date: 2024-06-10T16:53:10Z
• Authors: Man Hu; Shichuan Zhang; Yaqian Han; Hui Wu; Jin Gao; Haijun Wu; Qin Lin; Wei Shang; Xia Li; Hong Feng; Qiao Qiao; Guangyuan Hu; Kunyu Yang; Xicheng Song; Yuandong Cao; Min Kang; Ruozheng Wang; Jinming Yu
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e18013 Background: PD-1-based therapy has become the first-line standard treatment for R/M HNSCC, but KN-048 lacked data on mainland Chinese population. This study aims to conduct a pooled analysis of efficacy and safety pembrolizumab-based in patients (pts) with HNSCC from different regions China. Methods: Data comes 17 hospitals. pts who received pembrolizumab alone or combination chemotherapy/targeted July 2020 Jan 2023 were reviewed by searching hospital HIS/medical record system. The primary endpoint was OS, secondary endpoints include time (TOPT), safety, etc. Investigators also explored impact biomarkers survival. used SPSS 29 analyze data. Results: Total 160 included. Median age 60 yrs. 81.2% male, 95% had an ECOG 0-1 . Main tumor site showed: oral cavity (60.6%), larynx (12.5%), oropharynx (10.6%). 88.8% undergone surgery past, 65% RT. proportion only recurrence reached 75.6%. 79 (90.8%) CPS 1 more 44 (50.6%) 20 more. Other baseline information could be seen table. median follow-up 18.5 mos. 70.6% combined chemotherapy, 17.5% alone. 48 subsequently second-line treatment, than half which target-based treatments. OS all not reach, among mono group vs. chemotherapy (p=0.254). 18mo-OS monotherapy 69%, while 61% combination. No statistical difference mTOPT (6.0 vs 4.7 mos, p=0.644). results Cox Proportional Hazards Model suggest that score, smoking history, previous RT distant metastatic tumors related OS. Primary location, T stage, EGFR mutation TOPT. Studies have found significant correlation between survival prognosis. 28.1% experienced TRAEs, most common G1-4 myelosuppression (33.3%). main TRAEs G3-4 pneumonia (11.1%), bone marrow suppression (8.9%) abnormal liver function (4.4%). patient died due TRAEs. Conclusions: reflects real-world mOS local as population significantly higher KN-048, some clinical indicators prognosis found. In future, will further find valuable biomarkers. [Table: see text]